Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. - Wikidata - awgldk - TriplyDB

Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice.

Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice.

http://www.wikidata.org/entity/Q33293430

about

The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis Nucleic acid-based approaches to STAT inhibition Role of STAT3 in cancer metastasis and translational advances.STAT inhibitors for cancer therapy.Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention.Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp Progress towards the development of SH2 domain inhibitors.STAT3 signaling: anticancer strategies and challenges.Immune biomarkers of anti-EGFR monoclonal antibody therapy Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cells Photochemical control of DNA decoy function enables precise regulation of nuclear factor κB activity Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis Role of STAT3 in lung cancer.Lack of toxicity of a STAT3 decoy oligonucleotide.Overexpression of Bcl-2 induces STAT-3 activation via an increase in mitochondrial superoxide.TLR4 signaling promotes a COX-2/PGE2/STAT3 positive feedback loop in hepatocellular carcinoma (HCC) cells.MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in mice.First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression.Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling.STAT3 regulation of glioblastoma pathogenesis.Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects.Oligonucleotide delivery in cancer therapy.Targeting the tumor microenvironment by immunotherapy: part 2.New insights into the roles of ncRNA in the STAT3 pathway.Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature.The Role of STAT3 in Non-Small Cell Lung Cancer.Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer.Portrait of inflammatory response to ionizing radiation treatment.A STAT inhibitor patent review: progress since 2011.The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.Vectors and strategies for nonviral cancer gene therapy.Natural product pectolinarigenin inhibits osteosarcoma growth and metastasis via SHP-1-mediated STAT3 signaling inhibition.Berberine Increases Doxorubicin Sensitivity by Suppressing STAT3 in Lung Cancer.Blockage of STAT3 signaling pathway with a decoy oligodeoxynucleotide inhibits growth of human ovarian cancer cells.Off-target effects of plasmid-transcribed shRNAs on NFκB signaling pathway and cell survival of human melanoma cells.Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells.Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.Increase of the therapeutic effect on non-small-cell lung cancer cells with combination treatment of shRNA against Cyclin D1 and Bcl-xL in vitro.

P2860

Q24301084-62D24122-D4E8-4A51-ACCD-CE0FA277BF60 Q26822830-86579748-5857-416B-8B65-CA5F2D0DC963 Q31142794-149DC399-E06C-42FC-A49F-82EE986B17F7 Q33644206-CD8DD016-B8B2-47AE-8AAD-FCC788F3B67D Q33820278-7D227B38-7362-4360-81B8-50557B6C663F Q33934046-2E8FCB50-DB2F-4831-BAE9-6B6358C635C4 Q34581878-EE71855E-6BA7-441E-90D8-E80047C3C475 Q34715455-2BB300E0-1E70-4B39-BF06-762F7CCB71D1 Q34723594-5C91AC08-42C7-4626-8BF4-4758EABEF2ED Q34991240-6B3BC8AB-FC43-4750-9722-5F759E80A843 Q35169169-FF1EAC0E-3BC2-40D0-82E4-E5BBE6B11E43 Q35196919-9AFA8E07-5E15-4401-8557-5C6455B5C658 Q35673818-F4DDFF7B-4735-40CD-916A-A1B263C604C0 Q36086059-2B1B789C-FA2D-45D9-BA9D-9CE4A0F214E7 Q36175325-830A5EFA-91C6-44A2-B12C-B4C4729AAA71 Q36544047-569517A9-7EB1-41DF-B268-05AB88DEEB5D Q36710952-B1A78BA2-41E1-41F3-A0E4-B73C2955DAFB Q36769518-A783B4E2-51B9-4F79-8E9D-11C682A9AE1C Q36890491-9773DA26-B347-4638-B8AA-BFD168314BF6 Q36961488-3F869C48-72F4-4026-86DA-55FED9347310 Q37326692-DDB30266-746C-4AD2-A431-8D20AE69500C Q37550760-81847A01-271B-4C90-93AF-6D9FEC485B1B Q37633227-9FFD5E4C-C65B-4D26-BB1B-C8874EAC7A62 Q37803214-38603C38-3924-43BF-A56D-B04499FA4CC6 Q37952796-F6AD6451-A156-488E-B30C-A9D1EFB9DD48 Q38024125-3763F461-E9A2-4F90-8173-51F9A990E2FC Q38179031-E9496741-05B2-4429-B15F-27ACCF5B6615 Q38199934-55052F84-EAC8-4B92-A35E-D16568DB8406 Q38300047-E9EAFA3D-924E-4F82-AFF3-164F7295432F Q38364169-08D6E8DC-42F4-499D-8F74-88A87E89F04F Q38591166-08E831E6-8E68-41BD-ADC2-1BA945BFD570 Q38687571-1CAA1FE5-B979-40A6-B999-B3777474926A Q38694798-2644AC96-5B2A-4609-AD4C-3D405BC735C4 Q38741382-E90F24F4-5444-411B-99CD-1D005C5AEE7D Q38824752-8DC409D0-F174-4D20-B893-D296677E4425 Q39044466-0B85C081-F4B1-4668-8E8D-62464E3FA807 Q39068964-8DCA9A7D-655D-4338-9FE0-4DEA967AA686 Q39411350-6E4CB550-B510-4A91-963D-3D01E3991839 Q39819746-32D862E6-B92B-4308-9F21-3B65FA8CECC1 Q42324488-EA059A65-59A1-4CF1-8C57-06A538BD28C3

P2860

Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice.

http://www.wikidata.org/entity/Q33293430

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Therapeutic effects of STAT3 d ...... lung cancer in xenograft mice.

@ast

Therapeutic effects of STAT3 d ...... lung cancer in xenograft mice.

@en

type

label

Therapeutic effects of STAT3 d ...... lung cancer in xenograft mice.

@ast

Therapeutic effects of STAT3 d ...... lung cancer in xenograft mice.

@en

prefLabel

Therapeutic effects of STAT3 d ...... lung cancer in xenograft mice.

@ast

Therapeutic effects of STAT3 d ...... lung cancer in xenograft mice.

@en

P1433

Q33293430-06048AAD-BE94-4B3A-B33A-0806AF5C85CB

P1476

Q33293430-2E157024-3426-4221-B30D-2CBCE28A048F

P2093

Q33293430-01A0095C-7781-4246-9FE0-9C90EF1A2F9C

Q33293430-233DAB50-0AD1-4D4A-8354-A678BCF3CB3E

Q33293430-44DF85AA-CD6C-4303-9CBE-D3702C7756BC

Q33293430-489E2B29-8AFE-467F-8FF3-9A2129CDFA37

Q33293430-8B1F8DEA-F15C-4093-8F9E-C8F530010D4E

P2860

Q33293430-004CC4D0-9879-4C4F-ACE6-FF1D2BFDFCAB

Q33293430-00EF7CB4-EEAA-408A-981E-66E82DE76983

Q33293430-013703E4-2483-4EB5-BBCC-E494E5D172E6

Q33293430-039E2D74-A98A-4C9B-A1DF-F0D3679639F3

Q33293430-0F9BDBFC-EB61-4EF3-B577-91DC3D5DD563

Q33293430-2129DA2A-F4AE-49B3-9429-B7D573D3CC50

Q33293430-216BAC27-856A-4240-9927-3D5A048DD484

Q33293430-2B7D29D6-F1A9-4A6F-927F-6A8491341B17

Q33293430-2FCAF6B4-6740-4174-88A3-0626E202D821

Q33293430-35B15879-625B-4FBC-A73A-9C04E6896988

P2888

Q33293430-AAF73C98-894B-43B2-A016-8E5066ABD870

P304

Q33293430-AF63C3E0-3ADA-4BCE-AC6B-D65202E17F0A

P31

Q33293430-5153B136-9DF8-4A4A-9E22-AE94F8C3D75F

P356

Q33293430-CC008521-5F43-44E3-90CF-7344AF29C429

P407

Q33293430-6D9244D9-6459-4A34-BDF1-7F1360513737

P478

Q33293430-2E063FAB-FAF1-45F9-AEB9-C00110B7BEBD

P577

Q33293430-F76FB807-8F11-40FD-AC13-938CCEC332CD

P5875

Q33293430-26FB01F5-55A2-42D6-801B-0DB4F2007D60

P6179

Q33293430-7F5A10CD-341E-4794-AEAE-1E471AF08AB4

P698

Q33293430-C9C04A90-C50C-497A-96C2-42A197B4642E

P921

Q33293430-F37CF8BA-CC63-4D03-8A09-118B85B28CC6

P932

Q33293430-937DB67C-C6F2-4D1F-AB55-D4D83CEFF397

P356

1471-2407-7-149

P1433

P1476

Therapeutic effects of STAT3 d ...... lung cancer in xenograft mice.

@en

P2093

Haiming Wei

http://www.w3.org/2001/XMLSchema#string

Jian Zhang

http://www.w3.org/2001/XMLSchema#string

Lihua Wang

http://www.w3.org/2001/XMLSchema#string

Xulong Zhang

http://www.w3.org/2001/XMLSchema#string

Zhigang Tian

http://www.w3.org/2001/XMLSchema#string

P2860

Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells

Induction of epithelial tubules by growth factor HGF depends on the STAT pathway

Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression

Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6

STATs and gene regulation

The STATs of cancer--new molecular targets come of age

Stat3 as an oncogene

Targeted disruption of stat6 DNA binding activity by an oligonucleotide decoy blocks IL-4-driven T(H)2 cell response.

SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer

Toll-like receptor 3 ligand attenuates LPS-induced liver injury by down-regulation of toll-like receptor 4 expression on macrophages.

P2888

1471-2407-7-149

P304

149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-7-149

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2007-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6155124

http://www.w3.org/2001/XMLSchema#string

P6179

1029419314

http://www.w3.org/2001/XMLSchema#string

P698

17683579

http://www.w3.org/2001/XMLSchema#string

P921

P932

1988829

http://www.w3.org/2001/XMLSchema#string